Company Filing History:
Years Active: 2008-2015
Title: The Innovations of Johan Heilborn in Wound Healing
Introduction
Johan Heilborn is an accomplished inventor based in Stockholm, Sweden. With a remarkable portfolio of six patents, he has made significant contributions to the field of medical science, particularly in wound healing. His innovations leverage the properties of cathelicidin peptides, paving the way for advanced therapeutic options.
Latest Patents
Among his latest patents, Heilborn has developed a method utilizing the antimicrobial cathelicidin LL-37 and its derivatives for wound healing. Specifically, his research focuses on the use of cathelicidin peptide II-37, as well as N-terminal fragments and extended sequences of LL-37. These innovations aim to stimulate the proliferation of epithelial and stromal cells, thereby enhancing the healing of wounds, including chronic ulcers. Notably, he has also addressed the cytotoxic effects associated with LL-37 by incorporating bilayer-forming polar lipids, such as digalactosyldiacylglycerol, into pharmaceutical compositions and growth media.
Career Highlights
Johan Heilborn is currently associated with Lipopeptide AB, where he continues to explore the therapeutic potential of antimicrobial peptides. His dedication to research and development in this niche has positioned him as a pioneer in the utilization of cathelicidin peptides in healing therapies.
Collaborations
Heilborn collaborates with fellow researchers and colleagues such as Mona Ståhle-Bäckdahl and Anders Carlsson. Together, they delve into the complexities of wound healing and strive to turn innovative ideas into practical applications.
Conclusion
Johan Heilborn's contributions to the field of wound healing through his patented innovations provide a glimpse into the future of medical treatments. His work not only holds promise for improving patient outcomes but also emphasizes the importance of collaboration in advancing scientific understanding.